In early May 2026, Becton, Dickinson and Company reported higher quarterly sales of US$4.71 billion but swung to a net loss, raised its full-year adjusted earnings guidance, completed the divestiture ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the launch of the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform within its kidney stone care portfolio ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.

BD has picked a new executive to lead its planned connected care segment, as the company nears the conclusion of its years-long restructuring plan. The soon-to-be-consolidated unit is set to harbor BD ...

The scientific-instrument company Waters will deepen its biological sciences footprint by merging with the biosciences and diagnostic solution business of Becton, Dickinson (BD). The companies value ...